SCHEMBL2867561

SCHEMBL2867561

COc1ccccc1C(=O)NC(c1ccccc1)C1CCC(NS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
HPGD P15428 4/20 0.52
ALDH1A1 P00352 4/20 0.52
TP53 P04637 3/20 0.52
RAB9A P51151 2/20 0.52
HSD17B10 Q99714 1/20 0.52
LMNA P02545 3/20 0.50
GFER P55789 2/20 0.44
NPC1 O15118 1/20 0.44
AHR P35869 1/20 0.44
TSHR P16473 2/20 0.44
MAPK1 P28482 2/20 0.44
KCNA5 P22460 1/20 0.44
KDM4E B2RXH2 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.42
GLA P06280 1/20 0.42
KCNK3 O14649 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857096 0.87 HPGD (0.48) MAPTSMN1; SMN2HPGDALDH1A1TP53
SCHEMBL2857658 0.86 KMT2A (0.55) MAPTSMN1; SMN2HPGDALDH1A1TP53
SCHEMBL2854756 0.85 KCNA5 (0.49) MAPTSMN1; SMN2HPGDALDH1A1TP53
SCHEMBL2878387 0.84 KCNA5 (0.46) HPGDALDH1A1MAPK1KCNA5KMT2A
SCHEMBL2867485 0.83 KCNA5 (0.47) HPGDALDH1A1RAB9ANPC1MAPK1
SCHEMBL2853429 0.83 MAPT (0.44) MAPTSMN1; SMN2HPGDALDH1A1TP53
SCHEMBL2861504 0.82 ALDH1A1 (0.47) MAPTSMN1; SMN2HPGDALDH1A1TP53
SCHEMBL2858832 0.81 KCNA5 (0.45) MAPTSMN1; SMN2HPGDALDH1A1TP53
SCHEMBL5348976 0.79 KCNA5 (0.42) HPGDALDH1A1MAPK1KCNA5KMT2A
SCHEMBL2860891 0.79 KCNA5 (0.44) MAPTSMN1; SMN2HPGDALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function LLOYD JOHN 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function KCNJ2, KCNN3, KCNQ5 MAPT 3616/4885SMN1; SMN2 4281/4885HPGD 3115/4885
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 MAPT 3616/4885SMN1; SMN2 4281/4885HPGD 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.